{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:11:39Z","timestamp":1793686299744,"version":"4.5.1"},"reference-count":292,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004829","name":"Department of Science and Technology of Sichuan Province","doi-asserted-by":"publisher","award":["2024NSFSC1510"],"award-info":[{"award-number":["2024NSFSC1510"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Department of Science and Technology of Sichuan Province","doi-asserted-by":"publisher","award":["2024YFHZ0335"],"award-info":[{"award-number":["2024YFHZ0335"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["2024HXBH111"],"award-info":[{"award-number":["2024HXBH111"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>\n                    <jats:bold>Abstract<\/jats:bold>\n                  <\/jats:title>\n                  <jats:p>Human papillomaviruses, particularly high-risk human papillomaviruses, have been universally considered to be associated with the oncogenesis and progression of various cancers. The genome of human papillomaviruses is circular, double-stranded DNA that encodes early and late proteins. Each of the proteins is of crucial significance in infecting the epithelium of host cells persistently and supporting viral genome integrating into host cells. Notably, E6 and E7 proteins, classified as oncoproteins, trigger the incidence of cancers by fostering cell proliferation, hindering apoptosis, evading immune surveillance, promoting cell invasion, and disrupting the balance of cellular metabolism. Therefore, targeting human papillomaviruses and decoding molecular mechanisms by which human papillomaviruses drive carcinogenesis are of great necessity to better treat human papillomaviruses-related cancers. Human papillomaviruses have been applied clinically to different facets of human papillomavirus-related cancers, including prevention, screening, diagnosis, treatment, and prognosis. Several types of prophylactic vaccines have been publicly utilized worldwide and have greatly decreased the occurrence of human papillomavirus-related cancers, which have benefited numerous people. Although various therapeutic vaccines have been developed and tested clinically, none of them have been officially approved to date. Enhancing the efficacy of vaccines and searching for innovative technologies targeting human papillomaviruses remain critical challenges that warrant continuous research and attention in the future.<\/jats:p>","DOI":"10.1038\/s41392-024-02083-w","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T02:02:10Z","timestamp":1737684130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":130,"title":["Roles of human papillomavirus in cancers: oncogenic mechanisms and clinical use"],"prefix":"10.1038","volume":"10","author":[{"given":"Yu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"2083_CR1","doi-asserted-by":"crossref","unstructured":"G\u0142owienka-Stodolak, M. et al. Human papillomavirus infections and the role played by cervical and cervico-vaginal microbiota-evidence from next-generation sequencing studies. Cancers 16, 399 (2024).","DOI":"10.3390\/cancers16020399"},{"key":"2083_CR2","doi-asserted-by":"crossref","unstructured":"Har\u0119\u017ca, D. A., Wilczy\u0144ski, J. R. & Paradowska, E. Human papillomaviruses as infectious agents in gynecological cancers. oncogenic properties of viral proteins. Int. J. Mol. Sci. 23, 1818 (2022).","DOI":"10.3390\/ijms23031818"},{"key":"2083_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.virol.2004.03.033","volume":"324","author":"EM de Villiers","year":"2004","unstructured":"de Villiers, E. M., Fauquet, C., Broker, T. R., Bernard, H. U. & zur Hausen, H. Classification of papillomaviruses. Virology 324, 17\u201327 (2004).","journal-title":"Virology"},{"key":"2083_CR4","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.6004\/jnccn.2023.0062","volume":"21","author":"NR Abu-Rustum","year":"2023","unstructured":"Abu-Rustum, N. R. et al. NCCN Guidelines\u00ae insights: cervical cancer, version 1.2024. J. Natl. Compr. Cancer Netw. 21, 1224\u20131233 (2023).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"2083_CR5","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1080\/15548627.2020.1847444","volume":"17","author":"M Antonioli","year":"2021","unstructured":"Antonioli, M. et al. HPV sensitizes OPSCC cells to cisplatin-induced apoptosis by inhibiting autophagy through E7-mediated degradation of AMBRA1. Autophagy 17, 2842\u20132855 (2021).","journal-title":"Autophagy"},{"key":"2083_CR6","doi-asserted-by":"crossref","unstructured":"Bozec, A., Culi\u00e9, D., Poissonnet, G., Demard, F. & Dassonville, O. Current therapeutic strategies in patients with oropharyngeal squamous cell carcinoma: impact of the tumor HPV status. Cancers 13, 5456 (2021).","DOI":"10.3390\/cancers13215456"},{"key":"2083_CR7","first-page":"7","volume":"25","author":"A Meisels","year":"1981","unstructured":"Meisels, A. et al. Human papillomavirus infection of the cervix: the atypical condyloma. Acta Cytol. 25, 7\u201316 (1981).","journal-title":"Acta Cytol."},{"key":"2083_CR8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1177\/030089167806400513","volume":"64","author":"G Della Torre","year":"1978","unstructured":"Della Torre, G., Pilotti, S., de Palo, G. & Rilke, F. Viral particles in cervical condylomatous lesions. Tumori J. 64, 549\u2013553 (1978).","journal-title":"Tumori J."},{"key":"2083_CR9","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1073\/pnas.80.12.3812","volume":"80","author":"M D\u00fcrst","year":"1983","unstructured":"D\u00fcrst, M., Gissmann, L., Ikenberg, H. & zur Hausen, H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc. Natl. Acad. Sci. USA 80, 3812\u20133815 (1983).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2083_CR10","first-page":"251","volume":"1","author":"M D\u00fcrst","year":"1987","unstructured":"D\u00fcrst, M., Dzarlieva-Petrusevska, R. T., Boukamp, P., Fusenig, N. E. & Gissmann, L. Molecular and cytogenetic analysis of immortalized human primary keratinocytes obtained after transfection with human papillomavirus type 16 DNA. Oncogene 1, 251\u2013256 (1987).","journal-title":"Oncogene"},{"key":"2083_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/314111a0","volume":"314","author":"E Schwarz","year":"1985","unstructured":"Schwarz, E. et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 314, 111\u2013114 (1985).","journal-title":"Nature"},{"key":"2083_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"2083_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2020.106399","volume":"144","author":"L Bruni","year":"2021","unstructured":"Bruni, L. et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019. Prev. Med. 144, 106399 (2021).","journal-title":"Prev. Med."},{"key":"2083_CR14","doi-asserted-by":"publisher","first-page":"102524","DOI":"10.1016\/j.eclinm.2024.102524","volume":"70","author":"K Abbas","year":"2024","unstructured":"Abbas, K., Yoo, K. J., Prem, K. & Jit, M. Equity impact of HPV vaccination on lifetime projections of cervical cancer burden among cohorts in 84 countries by global, regional, and income levels, 2010-22: a modelling study. EClinicalMedicine 70, 102524 (2024).","journal-title":"EClinicalMedicine"},{"key":"2083_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0140-6736(20)30068-4","volume":"395","author":"M Brisson","year":"2020","unstructured":"Brisson, M. et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet 395, 575\u2013590 (2020).","journal-title":"Lancet"},{"key":"2083_CR16","doi-asserted-by":"crossref","unstructured":"Jensen, J. E., Becker, G. L., Jackson, J. B. & Rysavy, M. B. Human papillomavirus and associated cancers: a review. Viruses 16, 680 (2024).","DOI":"10.3390\/v16050680"},{"key":"2083_CR17","doi-asserted-by":"publisher","first-page":"djv086","DOI":"10.1093\/jnci\/djv086","volume":"107","author":"M Saraiya","year":"2015","unstructured":"Saraiya, M. et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J. Natl Cancer Inst. 107, djv086 (2015).","journal-title":"J. Natl Cancer Inst."},{"key":"2083_CR18","doi-asserted-by":"publisher","first-page":"1604621","DOI":"10.3389\/ijph.2022.1604621","volume":"67","author":"BWB Chua","year":"2022","unstructured":"Chua, B. W. B., Ma, V. Y., Alc\u00e1ntar-Fern\u00e1ndez, J. & Wee, H. L. Is it time to genotype beyond HPV16 and HPV18 for cervical cancer screening? Int. J. Public Health 67, 1604621 (2022).","journal-title":"Int. J. Public Health"},{"key":"2083_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.omto.2021.12.011","volume":"24","author":"R Tian","year":"2022","unstructured":"Tian, R. et al. Gene knock-out chain reaction enables high disruption efficiency of HPV18 E6\/E7 genes in cervical cancer cells. Mol. Ther. Oncolytics 24, 171\u2013179 (2022).","journal-title":"Mol. Ther. Oncolytics"},{"key":"2083_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103675","volume":"174","author":"R Bhattacharjee","year":"2022","unstructured":"Bhattacharjee, R. et al. Mechanistic role of HPV-associated early proteins in cervical cancer: molecular pathways and targeted therapeutic strategies. Crit. Rev. Oncol. Hematol. 174, 103675 (2022).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2083_CR21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0140-6736(24)01097-3","volume":"404","author":"F Wei","year":"2024","unstructured":"Wei, F., Georges, D., Man, I., Baussano, I. & Clifford, G. M. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. Lancet 404, 435\u2013444 (2024).","journal-title":"Lancet"},{"key":"2083_CR22","doi-asserted-by":"crossref","unstructured":"Lee, Y. M., Lee, B., Cho, N. H. & Park, J. H. Beyond the microscope: a technological overture for cervical cancer detection. Diagnostics 13, 3079 (2023).","DOI":"10.3390\/diagnostics13193079"},{"key":"2083_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"2083_CR24","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.30716","volume":"141","author":"C de Martel","year":"2017","unstructured":"de Martel, C., Plummer, M., Vignat, J. & Franceschi, S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int. J. Cancer 141, 664\u2013670 (2017).","journal-title":"Int. J. Cancer"},{"key":"2083_CR25","doi-asserted-by":"crossref","unstructured":"Williamson, A. L. Recent developments in human papillomavirus (HPV) vaccinology. Viruses 15, 1440 (2023).","DOI":"10.3390\/v15071440"},{"key":"2083_CR26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40618-023-02192-3","volume":"47","author":"A Garolla","year":"2024","unstructured":"Garolla, A., Graziani, A., Grande, G., Ortolani, C. & Ferlin, A. HPV-related diseases in male patients: an underestimated conundrum. J. Endocrinol. Investig. 47, 261\u2013274 (2024).","journal-title":"J. Endocrinol. Investig."},{"key":"2083_CR27","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41571-022-00603-7","volume":"19","author":"M Lechner","year":"2022","unstructured":"Lechner, M., Liu, J., Masterson, L. & Fenton, T. R. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat. Rev. Clin. Oncol. 19, 306\u2013327 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2083_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin, M. B. et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J. Clin. 67, 93\u201399 (2017).","journal-title":"CA Cancer J. Clin."},{"key":"2083_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/CMR.16.1.1-17.2003","volume":"16","author":"EM Burd","year":"2003","unstructured":"Burd, E. M. Human papillomavirus and cervical cancer. Clin. Microbiol. Rev. 16, 1\u201317 (2003).","journal-title":"Clin. Microbiol. Rev."},{"key":"2083_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00705-009-0310-3","volume":"154","author":"R Pereira","year":"2009","unstructured":"Pereira, R., Hitzeroth, I. I. & Rybicki, E. P. Insights into the role and function of L2, the minor capsid protein of papillomaviruses. Arch. Virol. 154, 187\u2013197 (2009).","journal-title":"Arch. Virol."},{"key":"2083_CR31","doi-asserted-by":"publisher","first-page":"5933","DOI":"10.1128\/jvi.65.11.5933-5943.1991","volume":"65","author":"T Chong","year":"1991","unstructured":"Chong, T., Apt, D., Gloss, B., Isa, M. & Bernard, H. U. The enhancer of human papillomavirus type 16: binding sites for the ubiquitous transcription factors oct-1, NFA, TEF-2, NF1, and AP-1 participate in epithelial cell-specific transcription. J. Virol. 65, 5933\u20135943 (1991).","journal-title":"J. Virol."},{"key":"2083_CR32","doi-asserted-by":"crossref","unstructured":"Yu, L., Majerciak, V. & Zheng, Z. M. HPV16 and HPV18 genome structure, expression, and post-transcriptional regulation. Int. J. Mol. Sci. 23, 4943 (2022).","DOI":"10.3390\/ijms23094943"},{"key":"2083_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1006\/viro.1995.1053","volume":"207","author":"M O\u2019Connor","year":"1995","unstructured":"O\u2019Connor, M. & Bernard, H. U. Oct-1 activates the epithelial-specific enhancer of human papillomavirus type 16 via a synergistic interaction with NFI at a conserved composite regulatory element. Virology 207, 77\u201388 (1995).","journal-title":"Virology"},{"key":"2083_CR34","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2021.18","volume":"23","author":"G Bletsa","year":"2021","unstructured":"Bletsa, G. et al. Genetic variability of the HPV16 early genes and LCR. Present and future perspectives. Expert Rev. Mol. Med. 23, e19 (2021).","journal-title":"Expert Rev. Mol. Med."},{"key":"2083_CR35","doi-asserted-by":"crossref","unstructured":"Warburton, A., Della Fera, A. N. & McBride, A. A. Dangerous liaisons: long-term replication with an extrachromosomal HPV genome. Viruses 13, 1846 (2021).","DOI":"10.3390\/v13091846"},{"key":"2083_CR36","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1002\/cpz1.235","volume":"1","author":"TL Coursey","year":"2021","unstructured":"Coursey, T. L. & McBride, A. A. Development of keratinocyte cell lines containing extrachromosomal human papillomavirus genomes. Curr. Protoc. 1, e235 (2021).","journal-title":"Curr. Protoc."},{"key":"2083_CR37","doi-asserted-by":"crossref","unstructured":"Della Fera, A. N., Warburton, A., Coursey, T. L., Khurana, S. & McBride, A. A. Persistent human papillomavirus infection. Viruses 13, 321 (2021).","DOI":"10.3390\/v13020321"},{"key":"2083_CR38","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1042\/CS20160786","volume":"131","author":"SV Graham","year":"2017","unstructured":"Graham, S. V. The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review. Clin. Sci. 131, 2201\u20132221 (2017).","journal-title":"Clin. Sci."},{"key":"2083_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.971","volume":"12","author":"R Tian","year":"2022","unstructured":"Tian, R. et al. Genome-wide virus-integration analysis reveals a common insertional mechanism of HPV, HBV and EBV. Clin. Transl. Med. 12, e971 (2022).","journal-title":"Clin. Transl. Med."},{"key":"2083_CR40","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/2159-8290.CD-22-0900","volume":"13","author":"K Akagi","year":"2023","unstructured":"Akagi, K. et al. Intratumoral heterogeneity and clonal evolution induced by HPV integration. Cancer Discov. 13, 910\u2013927 (2023).","journal-title":"Cancer Discov."},{"key":"2083_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30190-1","volume":"13","author":"L Zhou","year":"2022","unstructured":"Zhou, L. et al. Long-read sequencing unveils high-resolution HPV integration and its oncogenic progression in cervical cancer. Nat. Commun. 13, 2563 (2022).","journal-title":"Nat. Commun."},{"key":"2083_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e34999","volume":"10","author":"O Catal\u00e1n-Castorena","year":"2024","unstructured":"Catal\u00e1n-Castorena, O. et al. The role of HR-HPV integration in the progression of premalignant lesions into different cancer types. Heliyon 10, e34999 (2024).","journal-title":"Heliyon"},{"key":"2083_CR43","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/ng.3178","volume":"47","author":"Z Hu","year":"2015","unstructured":"Hu, Z. et al. Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism. Nat. Genet. 47, 158\u2013163 (2015).","journal-title":"Nat. Genet."},{"key":"2083_CR44","doi-asserted-by":"publisher","first-page":"e1006211","DOI":"10.1371\/journal.ppat.1006211","volume":"13","author":"AA McBride","year":"2017","unstructured":"McBride, A. A. & Warburton, A. The role of integration in oncogenic progression of HPV-associated cancers. PLoS Pathog. 13, e1006211 (2017).","journal-title":"PLoS Pathog."},{"key":"2083_CR45","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00151-22","volume":"10","author":"H Liu","year":"2022","unstructured":"Liu, H., Liang, H., Li, D., Wang, M. & Li, Y. Association of cervical dysbacteriosis, HPV oncogene expression, and cervical lesion progression. Microbiol. Spectr. 10, e0015122 (2022).","journal-title":"Microbiol. Spectr."},{"key":"2083_CR46","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","volume":"6","author":"DE Johnson","year":"2020","unstructured":"Johnson, D. E. et al. Head and neck squamous cell carcinoma. Nat. Rev. Dis. Prim. 6, 92 (2020).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2083_CR47","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.trsl.2022.09.004","volume":"253","author":"M Liu","year":"2023","unstructured":"Liu, M. et al. Long-read sequencing reveals oncogenic mechanism of HPV-human fusion transcripts in cervical cancer. Transl. Res. 253, 80\u201394 (2023).","journal-title":"Transl. Res."},{"key":"2083_CR48","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1158\/2159-8290.CD-23-0097","volume":"13","author":"AA McBride","year":"2023","unstructured":"McBride, A. A. & White, E. A. HPV integration can drive the formation of virus-host extrachromosomal DNA in tumors. Cancer Discov. 13, 814\u2013816 (2023).","journal-title":"Cancer Discov."},{"key":"2083_CR49","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1038\/s41388-023-02819-y","volume":"42","author":"YX Lim","year":"2023","unstructured":"Lim, Y. X., Mierzwa, M. L., Sartor, M. A. & D\u2019Silva, N. J. Clinical, morphologic and molecular heterogeneity of HPV-associated oropharyngeal cancer. Oncogene 42, 2939\u20132955 (2023).","journal-title":"Oncogene"},{"key":"2083_CR50","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41416-024-02655-1","volume":"131","author":"H Tabatabaeian","year":"2024","unstructured":"Tabatabaeian, H., Bai, Y., Huang, R., Chaurasia, A. & Darido, C. Navigating therapeutic strategies: HPV classification in head and neck cancer. Br. J. Cancer. 131, 220\u2013230 (2024).","journal-title":"Br. J. Cancer."},{"key":"2083_CR51","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1093\/nar\/gkad105","volume":"51","author":"R Tian","year":"2023","unstructured":"Tian, R. et al. HPV integration generates a cellular super-enhancer which functions as ecDNA to regulate genome-wide transcription. Nucleic Acids Res. 51, 4237\u20134251 (2023).","journal-title":"Nucleic Acids Res."},{"key":"2083_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-023-02926-9","volume":"24","author":"M Karimzadeh","year":"2023","unstructured":"Karimzadeh, M. et al. Human papillomavirus integration transforms chromatin to drive oncogenesis. Genome Biol. 24, 142 (2023).","journal-title":"Genome Biol."},{"key":"2083_CR53","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1038\/s41591-024-03014-6","volume":"30","author":"L Schreiberhuber","year":"2024","unstructured":"Schreiberhuber, L. et al. Cervical cancer screening using DNA methylation triage in a real-world population. Nat. Med. 30, 2251\u20132257 (2024).","journal-title":"Nat. Med."},{"key":"2083_CR54","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1038\/onc.2011.415","volume":"31","author":"CH Hsu","year":"2012","unstructured":"Hsu, C. H. et al. The HPV E6 oncoprotein targets histone methyltransferases for modulating specific gene transcription. Oncogene 31, 2335\u20132349 (2012).","journal-title":"Oncogene"},{"key":"2083_CR55","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.molcel.2004.12.016","volume":"17","author":"MC Thomas","year":"2005","unstructured":"Thomas, M. C. & Chiang, C. M. E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol. Cell 17, 251\u2013264 (2005).","journal-title":"Mol. Cell"},{"key":"2083_CR56","doi-asserted-by":"publisher","first-page":"188894","DOI":"10.1016\/j.bbcan.2023.188894","volume":"1878","author":"H Liu","year":"2023","unstructured":"Liu, H., Ma, H., Li, Y. & Zhao, H. Advances in epigenetic modifications and cervical cancer research. Biochim. Biophys. Acta Rev. Cancer 1878, 188894 (2023).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"2083_CR57","doi-asserted-by":"publisher","first-page":"e29685","DOI":"10.1002\/jmv.29685","volume":"96","author":"I Lo Cigno","year":"2024","unstructured":"Lo Cigno, I., Calati, F., Girone, C., Catozzo, M. & Gariglio, M. High-risk HPV oncoproteins E6 and E7 and their interplay with the innate immune response: uncovering mechanisms of immune evasion and therapeutic prospects. J. Med. Virol. 96, e29685 (2024).","journal-title":"J. Med. Virol."},{"key":"2083_CR58","doi-asserted-by":"crossref","unstructured":"Moody, C. A. Regulation of the innate immune response during the human papillomavirus life cycle. Viruses 14, 1797 (2022).","DOI":"10.3390\/v14081797"},{"key":"2083_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2022.100211","volume":"3","author":"J Fan","year":"2023","unstructured":"Fan, J. et al. Multi-omics characterization of silent and productive HPV integration in cervical cancer. Cell Genom. 3, 100211 (2023).","journal-title":"Cell Genom."},{"key":"2083_CR60","doi-asserted-by":"publisher","first-page":"955847","DOI":"10.3389\/fcimb.2022.955847","volume":"12","author":"F Baedyananda","year":"2022","unstructured":"Baedyananda, F., Sasivimolrattana, T., Chaiwongkot, A., Varadarajan, S. & Bhattarakosol, P. Role of HPV16 E1 in cervical carcinogenesis. Front. Cell Infect. Microbiol. 12, 955847 (2022).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"2083_CR61","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00281-019-00773-0","volume":"42","author":"M Burley","year":"2020","unstructured":"Burley, M., Roberts, S. & Parish, J. L. Epigenetic regulation of human papillomavirus transcription in the productive virus life cycle. Semin Immunopathol. 42, 159\u2013171 (2020).","journal-title":"Semin Immunopathol."},{"key":"2083_CR62","doi-asserted-by":"publisher","first-page":"11747","DOI":"10.1128\/JVI.01445-10","volume":"84","author":"A Fradet-Turcotte","year":"2010","unstructured":"Fradet-Turcotte, A., Moody, C., Laimins, L. A. & Archambault, J. Nuclear export of human papillomavirus type 31 E1 is regulated by Cdk2 phosphorylation and required for viral genome maintenance. J. Virol. 84, 11747\u201311760 (2010).","journal-title":"J. Virol."},{"key":"2083_CR63","doi-asserted-by":"publisher","first-page":"e0260841","DOI":"10.1371\/journal.pone.0260841","volume":"16","author":"F Baedyananda","year":"2021","unstructured":"Baedyananda, F., Chaiwongkot, A., Varadarajan, S. & Bhattarakosol, P. HPV16 E1 dysregulated cellular genes involved in cell proliferation and host DNA damage: a possible role in cervical carcinogenesis. PLoS ONE 16, e0260841 (2021).","journal-title":"PLoS ONE"},{"key":"2083_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-49886-4","volume":"9","author":"LJ Castro-Mu\u00f1oz","year":"2019","unstructured":"Castro-Mu\u00f1oz, L. J. et al. The human papillomavirus (HPV) E1 protein regulates the expression of cellular genes involved in immune response. Sci. Rep. 9, 13620 (2019).","journal-title":"Sci. Rep."},{"key":"2083_CR65","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.virol.2014.08.022","volume":"468","author":"JA Smith","year":"2014","unstructured":"Smith, J. A. et al. SMCX and components of the TIP60 complex contribute to E2 regulation of the HPV E6\/E7 promoter. Virology 468-470, 311\u2013321 (2014).","journal-title":"Virology"},{"key":"2083_CR66","doi-asserted-by":"publisher","first-page":"e486s","DOI":"10.6061\/clinics\/2018\/e486s","volume":"73","author":"AL Ribeiro","year":"2018","unstructured":"Ribeiro, A. L., Caodaglio, A. S. & Sichero, L. Regulation of HPV transcription. Clinics 73, e486s (2018).","journal-title":"Clinics"},{"key":"2083_CR67","doi-asserted-by":"crossref","unstructured":"Evande, R., Rana, A., Biswas-Fiss, E. E. & Biswas, S. B. Protein-DNA interactions regulate human papillomavirus DNA replication, transcription, and oncogenesis. Int. J. Mol. Sci. 24, 8493 (2023).","DOI":"10.3390\/ijms24108493"},{"key":"2083_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2017.03.002","volume":"34","author":"FCB Berti","year":"2017","unstructured":"Berti, F. C. B., Pereira, A. P. L., Cebinelli, G. C. M., Trugilo, K. P. & Braj\u00e3o de Oliveira, K. The role of interleukin 10 in human papilloma virus infection and progression to cervical carcinoma. Cytokine Growth Factor Rev. 34, 1\u201313 (2017).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2083_CR69","doi-asserted-by":"publisher","first-page":"12599","DOI":"10.1128\/JVI.02029-14","volume":"88","author":"EL Prescott","year":"2014","unstructured":"Prescott, E. L. et al. Human papillomavirus type 1 E1^E4 protein is a potent inhibitor of the serine-arginine (SR) protein kinase SRPK1 and inhibits phosphorylation of host SR proteins and of the viral transcription and replication regulator E2. J. Virol. 88, 12599\u201312611 (2014).","journal-title":"J. Virol."},{"key":"2083_CR70","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.virol.2013.07.008","volume":"445","author":"J Doorbar","year":"2013","unstructured":"Doorbar, J. The E4 protein; structure, function and patterns of expression. Virology 445, 80\u201398 (2013).","journal-title":"Virology"},{"key":"2083_CR71","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1002\/jmv.27829","volume":"94","author":"SR Sudarshan","year":"2022","unstructured":"Sudarshan, S. R., Schlegel, R. & Liu, X. Two conserved amino acids differentiate the biology of high-risk and low-risk HPV E5 proteins. J. Med. Virol. 94, 4565\u20134575 (2022).","journal-title":"J. Med. Virol."},{"key":"2083_CR72","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/rmv.1822","volume":"25","author":"J Doorbar","year":"2015","unstructured":"Doorbar, J., Egawa, N., Griffin, H., Kranjec, C. & Murakami, I. Human papillomavirus molecular biology and disease association. Rev. Med. Virol. 25, 2\u201323 (2015).","journal-title":"Rev. Med. Virol."},{"key":"2083_CR73","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0042-6822(03)00129-6","volume":"311","author":"GL Disbrow","year":"2003","unstructured":"Disbrow, G. L., Sunitha, I., Baker, C. C., Hanover, J. & Schlegel, R. Codon optimization of the HPV-16 E5 gene enhances protein expression. Virology 311, 105\u2013114 (2003).","journal-title":"Virology"},{"key":"2083_CR74","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.virol.2009.07.034","volume":"393","author":"L Hu","year":"2009","unstructured":"Hu, L. & Ceresa, B. P. Characterization of the plasma membrane localization and orientation of HPV16 E5 for cell-cell fusion. Virology 393, 135\u2013143 (2009).","journal-title":"Virology"},{"key":"2083_CR75","doi-asserted-by":"crossref","unstructured":"Basukala, O. & Banks, L. The not-so-good, the bad and the ugly: HPV E5, E6 and E7 oncoproteins in the orchestration of carcinogenesis. Viruses 13, 1892 (2021).","DOI":"10.3390\/v13101892"},{"key":"2083_CR76","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1006\/viro.1996.0475","volume":"223","author":"MC St\u00f6ppler","year":"1996","unstructured":"St\u00f6ppler, M. C., Straight, S. W., Tsao, G., Schlegel, R. & McCance, D. J. The E5 gene of HPV-16 enhances keratinocyte immortalization by full-length DNA. Virology 223, 251\u2013254 (1996).","journal-title":"Virology"},{"key":"2083_CR77","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13046-017-0541-1","volume":"36","author":"AC de Freitas","year":"2017","unstructured":"de Freitas, A. C., de Oliveira, T. H. A., Barros, M. R. Jr. & Venuti, A. hrHPV E5 oncoprotein: immune evasion and related immunotherapies. J. Exp. Clin. Cancer Res. 36, 71 (2017).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2083_CR78","doi-asserted-by":"publisher","first-page":"103923","DOI":"10.1016\/j.micpath.2019.103923","volume":"139","author":"NE Ilahi","year":"2020","unstructured":"Ilahi, N. E. & Bhatti, A. Impact of HPV E5 on viral life cycle via EGFR signaling. Micro. Pathog. 139, 103923 (2020).","journal-title":"Micro. Pathog."},{"key":"2083_CR79","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.virol.2013.05.006","volume":"445","author":"D DiMaio","year":"2013","unstructured":"DiMaio, D. & Petti, L. M. The E5 proteins. Virology 445, 99\u2013114 (2013).","journal-title":"Virology"},{"key":"2083_CR80","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1038\/sj.onc.1208453","volume":"24","author":"B Zhang","year":"2005","unstructured":"Zhang, B., Srirangam, A., Potter, D. A. & Roman, A. HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes. Oncogene 24, 2585\u20132588 (2005).","journal-title":"Oncogene"},{"key":"2083_CR81","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1007\/s00018-005-5561-x","volume":"63","author":"SH Kim","year":"2006","unstructured":"Kim, S. H. et al. Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK\/ ERK1,2 and PI3K\/Akt. Cell Mol. Life Sci. 63, 930\u2013938 (2006).","journal-title":"Cell Mol. Life Sci."},{"key":"2083_CR82","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/jmv.25624","volume":"92","author":"DL Basto","year":"2020","unstructured":"Basto, D. L. et al. The papillomavirus E5 gene does not affect EGFR transcription and overall survival in cervical cancer. J. Med Virol. 92, 1283\u20131289 (2020).","journal-title":"J. Med Virol."},{"key":"2083_CR83","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bbcan.2019.04.003","volume":"1872","author":"F Bejjani","year":"2019","unstructured":"Bejjani, F., Evanno, E., Zibara, K., Piechaczyk, M. & Jariel-Encontre, I. The AP-1 transcriptional complex: local switch or remote command? Biochim Biophys. Acta Rev. Cancer 1872, 11\u201323 (2019).","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"key":"2083_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-10-39","volume":"10","author":"S Mahata","year":"2011","unstructured":"Mahata, S. et al. Berberine modulates AP-1 activity to suppress HPV transcription and downstream signaling to induce growth arrest and apoptosis in cervical cancer cells. Mol. Cancer 10, 39 (2011).","journal-title":"Mol. Cancer"},{"key":"2083_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2023.166817","volume":"1869","author":"K Thakur","year":"2023","unstructured":"Thakur, K. et al. Physical interaction between STAT3 and AP1 in cervical carcinogenesis: Implications in HPV transcription control. Biochim Biophys. Acta Mol. Basis Dis. 1869, 166817 (2023).","journal-title":"Biochim Biophys. Acta Mol. Basis Dis."},{"key":"2083_CR86","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s13046-020-01714-8","volume":"39","author":"Z Yang","year":"2020","unstructured":"Yang, Z. et al. RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer. J. Exp. Clin. Cancer Res. 39, 203 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2083_CR87","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1158\/1541-7786.MCR-20-0491","volume":"19","author":"L Gutierrez-Xicotencatl","year":"2021","unstructured":"Gutierrez-Xicotencatl, L. et al. Cellular functions of HPV16 E5 oncoprotein during oncogenic transformation. Mol. Cancer Res. 19, 167\u2013179 (2021).","journal-title":"Mol. Cancer Res."},{"key":"2083_CR88","doi-asserted-by":"publisher","first-page":"4963","DOI":"10.1038\/onc.2011.203","volume":"30","author":"F Belleudi","year":"2011","unstructured":"Belleudi, F. et al. HPV16 E5 affects the KGFR\/FGFR2b-mediated epithelial growth through alteration of the receptor expression, signaling and endocytic traffic. Oncogene 30, 4963\u20134976 (2011).","journal-title":"Oncogene"},{"key":"2083_CR89","doi-asserted-by":"publisher","first-page":"e2169","DOI":"10.1002\/rmv.2169","volume":"31","author":"AK Aranda-Rivera","year":"2021","unstructured":"Aranda-Rivera, A. K., Cruz-Gregorio, A., Briones-Herrera, A. & Pedraza-Chaverri, J. Regulation of autophagy by high- and low-risk human papillomaviruses. Rev. Med. Virol. 31, e2169 (2021).","journal-title":"Rev. Med. Virol."},{"key":"2083_CR90","first-page":"1191","volume":"85","author":"AV Zamaraev","year":"2020","unstructured":"Zamaraev, A. V., Zhivotovsky, B. & Kopeina, G. S. Viral infections: negative regulators of apoptosis and oncogenic factors. Biochemistry 85, 1191\u20131201 (2020).","journal-title":"Biochemistry"},{"key":"2083_CR91","doi-asserted-by":"publisher","first-page":"e1011171","DOI":"10.1371\/journal.ppat.1011171","volume":"19","author":"MI Khalil","year":"2023","unstructured":"Khalil, M. I. et al. HPV upregulates MARCHF8 ubiquitin ligase and inhibits apoptosis by degrading the death receptors in head and neck cancer. PLoS Pathog. 19, e1011171 (2023).","journal-title":"PLoS Pathog."},{"key":"2083_CR92","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/s41423-020-00630-3","volume":"18","author":"D Bertheloot","year":"2021","unstructured":"Bertheloot, D., Latz, E. & Franklin, B. S. Necroptosis, pyroptosis and apoptosis: an intricate game of cell death. Cell Mol. Immunol. 18, 1106\u20131121 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"2083_CR93","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","volume":"17","author":"BA Carneiro","year":"2020","unstructured":"Carneiro, B. A. & El-Deiry, W. S. Targeting apoptosis in cancer therapy. Nat. Rev. Clin. Oncol. 17, 395\u2013417 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2083_CR94","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000076642","volume":"47","author":"K Kabsch","year":"2004","unstructured":"Kabsch, K. et al. The HPV-16 E5 protein inhibits TRAIL- and FasL-mediated apoptosis in human keratinocyte raft cultures. Intervirology 47, 48\u201356 (2004).","journal-title":"Intervirology"},{"key":"2083_CR95","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/carcin\/bgp318","volume":"31","author":"JM Oh","year":"2010","unstructured":"Oh, J. M. et al. Human papillomavirus type 16 E5 protein inhibits hydrogen-peroxide-induced apoptosis by stimulating ubiquitin-proteasome-mediated degradation of Bax in human cervical cancer cells. Carcinogenesis 31, 402\u2013410 (2010).","journal-title":"Carcinogenesis"},{"key":"2083_CR96","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.virusres.2006.02.005","volume":"120","author":"GH Ashrafi","year":"2006","unstructured":"Ashrafi, G. H., Brown, D. R., Fife, K. H. & Campo, M. S. Down-regulation of MHC class I is a property common to papillomavirus E5 proteins. Virus Res. 120, 208\u2013211 (2006).","journal-title":"Virus Res."},{"key":"2083_CR97","doi-asserted-by":"crossref","unstructured":"Jain, M. et al. Epidemiology, molecular pathogenesis, immuno-pathogenesis, immune escape mechanisms and vaccine evaluation for HPV-associated carcinogenesis. Pathogens 12, 1380 (2023).","DOI":"10.3390\/pathogens12121380"},{"key":"2083_CR98","doi-asserted-by":"publisher","first-page":"11614","DOI":"10.1128\/JVI.01053-10","volume":"84","author":"S Miura","year":"2010","unstructured":"Miura, S. et al. CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV. J. Virol. 84, 11614\u201311623 (2010).","journal-title":"J. Virol."},{"key":"2083_CR99","doi-asserted-by":"crossref","unstructured":"Scarth, J. A., Patterson, M. R., Morgan, E. L. & Macdonald, A. The human papillomavirus oncoproteins: a review of the host pathways targeted on the road to transformation. J. Gen. Virol. 102, 001540 (2021).","DOI":"10.1099\/jgv.0.001540"},{"key":"2083_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112508","volume":"42","author":"S Miyauchi","year":"2023","unstructured":"Miyauchi, S. et al. Human papillomavirus E5 suppresses immunity via inhibition of the immunoproteasome and STING pathway. Cell Rep. 42, 112508 (2023).","journal-title":"Cell Rep."},{"key":"2083_CR101","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1038\/sj.onc.1210916","volume":"27","author":"N Kivi","year":"2008","unstructured":"Kivi, N., Greco, D., Auvinen, P. & Auvinen, E. Genes involved in cell adhesion, cell motility and mitogenic signaling are altered due to HPV 16 E5 protein expression. Oncogene 27, 2532\u20132541 (2008).","journal-title":"Oncogene"},{"key":"2083_CR102","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3892\/or.2012.2106","volume":"29","author":"S Liao","year":"2013","unstructured":"Liao, S. et al. Human papillomavirus 16\/18 E5 promotes cervical cancer cell proliferation, migration and invasion in vitro and accelerates tumor growth in vivo. Oncol. Rep. 29, 95\u2013102 (2013).","journal-title":"Oncol. Rep."},{"key":"2083_CR103","doi-asserted-by":"crossref","unstructured":"Barillari, G., Monini, P., Sgadari, C. & Ensoli, B. The impact of human papilloma viruses, matrix metallo-proteinases and HIV protease inhibitors on the onset and progression of uterine cervix epithelial tumors: a review of preclinical and clinical studies. Int. J. Mol. Sci. 19, 1418 (2018).","DOI":"10.3390\/ijms19051418"},{"key":"2083_CR104","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/ijc.29373","volume":"137","author":"D Ranieri","year":"2015","unstructured":"Ranieri, D., Belleudi, F., Magenta, A. & Torrisi, M. R. HPV16 E5 expression induces switching from FGFR2b to FGFR2c and epithelial-mesenchymal transition. Int. J. Cancer 137, 61\u201372 (2015).","journal-title":"Int. J. Cancer"},{"key":"2083_CR105","doi-asserted-by":"publisher","first-page":"188646","DOI":"10.1016\/j.bbcan.2021.188646","volume":"1877","author":"K Sitarz","year":"2022","unstructured":"Sitarz, K., Czamara, K., Szostek, S. & Kaczor, A. The impact of HPV infection on human glycogen and lipid metabolism\u2014a review. Biochim Biophys. Acta Rev. Cancer 1877, 188646 (2022).","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"key":"2083_CR106","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.3390\/v7072785","volume":"7","author":"K Ganti","year":"2015","unstructured":"Ganti, K. et al. The human papillomavirus E6 PDZ binding motif: from life cycle to malignancy. Viruses 7, 3530\u20133551 (2015).","journal-title":"Viruses"},{"key":"2083_CR107","doi-asserted-by":"crossref","unstructured":"Conrady, M. C. et al. Structure of high-risk papillomavirus 31 E6 oncogenic protein and characterization of E6\/E6AP\/p53 complex formation. J. Virol. 95, 10\u20131128 (2020).","DOI":"10.1128\/JVI.00730-20"},{"key":"2083_CR108","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nature16481","volume":"529","author":"D Martinez-Zapien","year":"2016","unstructured":"Martinez-Zapien, D. et al. Structure of the E6\/E6AP\/p53 complex required for HPV-mediated degradation of p53. Nature 529, 541\u2013545 (2016).","journal-title":"Nature"},{"key":"2083_CR109","doi-asserted-by":"publisher","first-page":"10002","DOI":"10.1073\/pnas.170093297","volume":"97","author":"S Duensing","year":"2000","unstructured":"Duensing, S. et al. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc. Natl. Acad. Sci. USA 97, 10002\u201310007 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2083_CR110","doi-asserted-by":"crossref","unstructured":"D\u00edaz, L. et al. The phytochemical \u03b1-mangostin inhibits cervical cancer cell proliferation and tumor growth by downregulating E6\/E7-HPV oncogenes and KCNH1 gene expression. Int. J. Mol. Sci. 24, 3055 (2023).","DOI":"10.3390\/ijms24033055"},{"key":"2083_CR111","doi-asserted-by":"crossref","unstructured":"Zhao, X. et al. Curcumin suppressed the proliferation and apoptosis of HPV-positive cervical cancer cells by directly targeting the E6 protein. Phytother Res. 38, 4967\u20134981 (2023).","DOI":"10.1002\/ptr.7868"},{"key":"2083_CR112","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/nar\/gkv927","volume":"44","author":"M Fischer","year":"2016","unstructured":"Fischer, M., Quaas, M., Steiner, L. & Engeland, K. The p53-p21-DREAM-CDE\/CHR pathway regulates G2\/M cell cycle genes. Nucleic Acids Res. 44, 164\u2013174 (2016).","journal-title":"Nucleic Acids Res."},{"key":"2083_CR113","doi-asserted-by":"publisher","first-page":"5061","DOI":"10.1093\/emboj\/18.18.5061","volume":"18","author":"D Patel","year":"1999","unstructured":"Patel, D., Huang, S. M., Baglia, L. A. & McCance, D. J. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J. 18, 5061\u20135072 (1999).","journal-title":"EMBO J."},{"key":"2083_CR114","doi-asserted-by":"publisher","DOI":"10.1186\/s13027-020-00295-7","volume":"15","author":"S Tavakolian","year":"2020","unstructured":"Tavakolian, S., Goudarzi, H. & Faghihloo, E. Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers. Infect. Agent Cancer 15, 27 (2020).","journal-title":"Infect. Agent Cancer"},{"key":"2083_CR115","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.bbagrm.2014.03.013","volume":"1849","author":"G Bretones","year":"2015","unstructured":"Bretones, G., Delgado, M. D. & Le\u00f3n, J. Myc and cell cycle control. Biochim Biophys. Acta 1849, 506\u2013516 (2015).","journal-title":"Biochim Biophys. Acta"},{"key":"2083_CR116","doi-asserted-by":"crossref","unstructured":"Bossler, F., Hoppe-Seyler, K. & Hoppe-Seyler, F. PI3K\/AKT\/mTOR signaling regulates the virus\/host cell crosstalk in HPV-positive cervical cancer cells. Int. J. Mol. Sci. 20, 2188 (2019).","DOI":"10.3390\/ijms20092188"},{"key":"2083_CR117","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0361-x","volume":"14","author":"L Zhang","year":"2015","unstructured":"Zhang, L., Wu, J., Ling, M. T., Zhao, L. & Zhao, K. N. The role of the PI3K\/Akt\/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses. Mol. Cancer 14, 87 (2015).","journal-title":"Mol. Cancer"},{"key":"2083_CR118","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1007\/s11010-021-04211-4","volume":"476","author":"Y Zheng","year":"2021","unstructured":"Zheng, Y. et al. Effects of miR-202-5p silencing PIK3CA gene expression on proliferation, invasion, and epithelial-mesenchymal transition of cervical cancer SiHa cells through inhibiting PI3K\/Akt\/mTOR signaling pathway activation. Mol. Cell Biochem. 476, 4031\u20134044 (2021).","journal-title":"Mol. Cell Biochem."},{"key":"2083_CR119","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-019-0942-7","volume":"19","author":"Y Jin","year":"2019","unstructured":"Jin, Y., Li, Y., Wang, X. & Yang, Y. Secretory leukocyte protease inhibitor suppresses HPV E6-expressing HNSCC progression by mediating NF-\u03baB and Akt pathways. Cancer Cell Int. 19, 220 (2019).","journal-title":"Cancer Cell Int."},{"key":"2083_CR120","doi-asserted-by":"publisher","first-page":"9486","DOI":"10.1128\/JVI.05007-11","volume":"85","author":"S Hong","year":"2011","unstructured":"Hong, S., Mehta, K. P. & Laimins, L. A. Suppression of STAT-1 expression by human papillomaviruses is necessary for differentiation-dependent genome amplification and plasmid maintenance. J. Virol. 85, 9486\u20139494 (2011).","journal-title":"J. Virol."},{"key":"2083_CR121","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202101232RR","volume":"35","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. Orthogonal ubiquitin transfer reveals human papillomavirus E6 downregulates nuclear transport to disarm interferon-\u03b3 dependent apoptosis of cervical cancer cells. FASEB J. 35, e21986 (2021).","journal-title":"FASEB J."},{"key":"2083_CR122","doi-asserted-by":"crossref","unstructured":"Bordignon, V. et al. How human papillomavirus replication and immune evasion strategies take advantage of the host DNA damage repair machinery. Viruses 9, 390 (2017).","DOI":"10.3390\/v9120390"},{"key":"2083_CR123","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.579629","volume":"8","author":"M Zhang","year":"2020","unstructured":"Zhang, M. et al. Fra-1 inhibits cell growth and the Warburg effect in cervical cancer cells via STAT1 regulation of the p53 signaling pathway. Front. Cell Dev. Biol. 8, 579629 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"2083_CR124","doi-asserted-by":"publisher","first-page":"e1007835","DOI":"10.1371\/journal.ppat.1007835","volume":"15","author":"EL Morgan","year":"2019","unstructured":"Morgan, E. L. & Macdonald, A. Autocrine STAT3 activation in HPV positive cervical cancer through a virus-driven Rac1-NF\u03baB-IL-6 signalling axis. PLoS Pathog. 15, e1007835 (2019).","journal-title":"PLoS Pathog."},{"key":"2083_CR125","doi-asserted-by":"publisher","first-page":"e67849","DOI":"10.1371\/journal.pone.0067849","volume":"8","author":"S Shukla","year":"2013","unstructured":"Shukla, S. et al. Functional regulatory role of STAT3 in HPV16-mediated cervical carcinogenesis. PLoS ONE 8, e67849 (2013).","journal-title":"PLoS ONE"},{"key":"2083_CR126","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson, D. E., O\u2019Keefe, R. A. & Grandis, J. R. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15, 234\u2013248 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2083_CR127","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29230","volume":"95","author":"TD Strobel","year":"2023","unstructured":"Strobel, T. D. et al. Revisiting the role of endogenous STAT3 in HPV-positive cervical cancer cells. J. Med Virol. 95, e29230 (2023).","journal-title":"J. Med Virol."},{"key":"2083_CR128","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28624","volume":"95","author":"J Skelin","year":"2023","unstructured":"Skelin, J. et al. MAML1-induced HPV E6 oncoprotein stability is required for cellular proliferation and migration of cervical tumor-derived cells. J. Med. Virol. 95, e28624 (2023).","journal-title":"J. Med. Virol."},{"key":"2083_CR129","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/jcp.10217","volume":"194","author":"S Weijzen","year":"2003","unstructured":"Weijzen, S., Zlobin, A., Braid, M., Miele, L. & Kast, W. M. HPV16 E6 and E7 oncoproteins regulate Notch-1 expression and cooperate to induce transformation. J. Cell Physiol. 194, 356\u2013362 (2003).","journal-title":"J. Cell Physiol."},{"key":"2083_CR130","doi-asserted-by":"publisher","first-page":"e1007575","DOI":"10.1371\/journal.ppat.1007575","volume":"15","author":"CM Drews","year":"2019","unstructured":"Drews, C. M., Case, S. & Vande Pol, S. B. E6 proteins from high-risk HPV, low-risk HPV, and animal papillomaviruses activate the Wnt\/\u03b2-catenin pathway through E6AP-dependent degradation of NHERF1. PLoS Pathog. 15, e1007575 (2019).","journal-title":"PLoS Pathog."},{"key":"2083_CR131","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.3390\/v7082842","volume":"7","author":"JO Bello","year":"2015","unstructured":"Bello, J. O. et al. Regulation of the Wnt\/\u03b2-catenin signaling pathway by human papillomavirus E6 and E7 oncoproteins. Viruses 7, 4734\u20134755 (2015).","journal-title":"Viruses"},{"key":"2083_CR132","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Bello, J. O. et al. HPV-18 E6 oncoprotein and its spliced isoform E6*I regulate the Wnt\/\u03b2-catenin cell signaling pathway through the TCF-4 transcriptional factor. Int. J. Mol. Sci. 19, 3153 (2018).","DOI":"10.3390\/ijms19103153"},{"key":"2083_CR133","doi-asserted-by":"publisher","first-page":"e29315","DOI":"10.1002\/jmv.29315","volume":"95","author":"J Skelin","year":"2023","unstructured":"Skelin, J., Luk, H. Y., Butorac, D., Boon, S. S. & Tomai\u0107, V. The effects of HPV oncoproteins on host communication networks: therapeutic connotations. J. Med. Virol. 95, e29315 (2023).","journal-title":"J. Med. Virol."},{"key":"2083_CR134","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13046-020-01745-1","volume":"39","author":"JJ Qiu","year":"2020","unstructured":"Qiu, J. J., Sun, S. G., Tang, X. Y., Lin, Y. Y. & Hua, K. Q. Extracellular vesicular Wnt7b mediates HPV E6-induced cervical cancer angiogenesis by activating the \u03b2-catenin signaling pathway. J. Exp. Clin. Cancer Res. 39, 260 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2083_CR135","doi-asserted-by":"crossref","unstructured":"Ortiz-Pedraza, Y. et al. HPV16 E6 and E7 oncoproteins stimulate the glutamine pathway maintaining cell proliferation in a SNAT1-dependent fashion. Viruses 15, 324 (2023).","DOI":"10.3390\/v15020324"},{"key":"2083_CR136","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1002\/cbin.12020","volume":"47","author":"G Nie","year":"2023","unstructured":"Nie, G. et al. HPV E6 promotes cell proliferation of cervical cancer cell by accelerating accumulation of RBM15 dependently of autophagy inhibition. Cell Biol. Int. 47, 1327\u20131343 (2023).","journal-title":"Cell Biol. Int."},{"key":"2083_CR137","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1038\/s41388-017-0083-1","volume":"37","author":"E Peta","year":"2018","unstructured":"Peta, E. et al. HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC\/miR-146a-5p axys. Oncogene 37, 1654\u20131668 (2018).","journal-title":"Oncogene"},{"key":"2083_CR138","doi-asserted-by":"crossref","unstructured":"Choi, P. W. et al. The dysregulation of microRNAs in the development of cervical pre-cancer-an update. Int. J. Mol. Sci. 23, 7126 (2022).","DOI":"10.3390\/ijms23137126"},{"key":"2083_CR139","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1002\/ijc.31876","volume":"144","author":"Q Wang","year":"2019","unstructured":"Wang, Q. et al. HPV16 E6 promotes cervical cancer cell migration and invasion by downregulation of NHERF1. Int. J. Cancer 144, 1619\u20131632 (2019).","journal-title":"Int. J. Cancer"},{"key":"2083_CR140","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41580-022-00465-y","volume":"23","author":"CE Buckley","year":"2022","unstructured":"Buckley, C. E. & St Johnston, D. Apical-basal polarity and the control of epithelial form and function. Nat. Rev. Mol. Cell Biol. 23, 559\u2013577 (2022).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2083_CR141","doi-asserted-by":"crossref","unstructured":"W\u00f6rthm\u00fcller, J. & R\u00fcegg, C. MAGI1, a scaffold protein with tumor suppressive and vascular functions. Cells 10, 1494 (2021).","DOI":"10.3390\/cells10061494"},{"key":"2083_CR142","doi-asserted-by":"publisher","first-page":"5270","DOI":"10.1038\/sj.onc.1203906","volume":"19","author":"BA Glaunsinger","year":"2000","unstructured":"Glaunsinger, B. A., Lee, S. S., Thomas, M., Banks, L. & Javier, R. Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins. Oncogene 19, 5270\u20135280 (2000).","journal-title":"Oncogene"},{"key":"2083_CR143","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/cbin.11756","volume":"46","author":"Y Lu","year":"2022","unstructured":"Lu, Y. et al. HPV16 E6 promotes cell proliferation, migration, and invasion of human cervical cancer cells by elevating both EMT and stemness characteristics. Cell Biol. Int. 46, 599\u2013610 (2022).","journal-title":"Cell Biol. Int."},{"key":"2083_CR144","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22655-6","volume":"12","author":"H Wei","year":"2021","unstructured":"Wei, H. et al. Structural insight into the molecular mechanism of p53-mediated mitochondrial apoptosis. Nat. Commun. 12, 2280 (2021).","journal-title":"Nat. Commun."},{"key":"2083_CR145","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","volume":"8","author":"H Wang","year":"2023","unstructured":"Wang, H., Guo, M., Wei, H. & Chen, Y. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct. Target Ther. 8, 92 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2083_CR146","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/sj.cdd.4401886","volume":"13","author":"TO Garnett","year":"2006","unstructured":"Garnett, T. O., Filippova, M. & Duerksen-Hughes, P. J. Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis. Cell Death Differ. 13, 1915\u20131926 (2006).","journal-title":"Cell Death Differ."},{"key":"2083_CR147","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","volume":"18","author":"LB Ivashkiv","year":"2018","unstructured":"Ivashkiv, L. B. IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat. Rev. Immunol. 18, 545\u2013558 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"2083_CR148","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.587132","volume":"10","author":"RAM Rossetti","year":"2020","unstructured":"Rossetti, R. A. M. et al. Local and systemic STAT3 and p65 NF-KappaB expression as progression markers and functional targets for patients with cervical cancer. Front. Oncol. 10, 587132 (2020).","journal-title":"Front. Oncol."},{"key":"2083_CR149","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01875-21","volume":"96","author":"J Poirson","year":"2022","unstructured":"Poirson, J. et al. High-risk mucosal human papillomavirus 16 (HPV16) E6 protein and cutaneous HPV5 and HPV8 E6 proteins employ distinct strategies to interfere with interferon regulatory factor 3-mediated beta interferon expression. J. Virol. 96, e0187521 (2022).","journal-title":"J. Virol."},{"key":"2083_CR150","doi-asserted-by":"publisher","first-page":"18780","DOI":"10.1073\/pnas.0906357106","volume":"106","author":"X Liu","year":"2009","unstructured":"Liu, X. et al. HPV E6 protein interacts physically and functionally with the cellular telomerase complex. Proc. Natl. Acad. Sci. USA 106, 18780\u201318785 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2083_CR151","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1101\/gad.1214704","volume":"18","author":"L Gewin","year":"2004","unstructured":"Gewin, L., Myers, H., Kiyono, T. & Galloway, D. A. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6\/E6-AP complex. Genes Dev. 18, 2269\u20132282 (2004).","journal-title":"Genes Dev."},{"key":"2083_CR152","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28681","volume":"95","author":"A Wang","year":"2023","unstructured":"Wang, A. et al. Overexpression of the telomerase holoenzyme induces EMT and tumorigenesis of HPV-immortalized keratinocytes. J. Med. Virol. 95, e28681 (2023).","journal-title":"J. Med. Virol."},{"key":"2083_CR153","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.canlet.2019.02.024","volume":"449","author":"PA Vliet-Gregg","year":"2019","unstructured":"Vliet-Gregg, P. A., Robinson, K. L., Levan, J., Matsumoto, L. R. & Katzenellenbogen, R. A. NFX1-123 is highly expressed in cervical cancer and increases growth and telomerase activity in HPV 16E6 expressing cells. Cancer Lett. 449, 106\u2013113 (2019).","journal-title":"Cancer Lett."},{"key":"2083_CR154","doi-asserted-by":"crossref","unstructured":"Boon, S. S. et al. Interaction between human papillomavirus-encoded E6 protein and AurB induces cell immortalization and proliferation\u2014a potential target of intervention. Cancers 15, 2465 (2023).","DOI":"10.3390\/cancers15092465"},{"key":"2083_CR155","doi-asserted-by":"crossref","unstructured":"Priego-Hern\u00e1ndez, V. D. et al. Expression of HIF-1\u03b1 and genes involved in glucose metabolism is increased in cervical cancer and HPV-16-positive cell lines. Pathogens 12, 33 (2022).","DOI":"10.3390\/pathogens12010033"},{"key":"2083_CR156","doi-asserted-by":"publisher","first-page":"507","DOI":"10.7150\/ijbs.67770","volume":"18","author":"C Hu","year":"2022","unstructured":"Hu, C. et al. HPV E6\/E7 promotes aerobic glycolysis in cervical cancer by regulating IGF2BP2 to stabilize m(6)A-MYC expression. Int. J. Biol. Sci. 18, 507\u2013521 (2022).","journal-title":"Int. J. Biol. Sci."},{"key":"2083_CR157","first-page":"783","volume":"19","author":"Y Xie","year":"2019","unstructured":"Xie, Y. et al. PI3K\/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia (review). Mol. Med. Rep. 19, 783\u2013791 (2019).","journal-title":"Mol. Med. Rep."},{"key":"2083_CR158","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.freeradbiomed.2021.06.009","volume":"172","author":"A Cruz-Gregorio","year":"2021","unstructured":"Cruz-Gregorio, A., Aranda-Rivera, A. K., Ortega-Lozano, A. J., Pedraza-Chaverri, J. & Mendoza-Hoffmann, F. Lipid metabolism and oxidative stress in HPV-related cancers. Free Radic. Biol. Med. 172, 226\u2013236 (2021).","journal-title":"Free Radic. Biol. Med."},{"key":"2083_CR159","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/0092-8674(88)90570-3","volume":"53","author":"WC Phelps","year":"1988","unstructured":"Phelps, W. C., Yee, C. L., M\u00fcnger, K. & Howley, P. M. The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell 53, 539\u2013547 (1988).","journal-title":"Cell"},{"key":"2083_CR160","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1128\/jvi.67.6.3142-3150.1993","volume":"67","author":"MC McIntyre","year":"1993","unstructured":"McIntyre, M. C., Frattini, M. G., Grossman, S. R. & Laimins, L. A. Human papillomavirus type 18 E7 protein requires intact Cys-X-X-Cys motifs for zinc binding, dimerization, and transformation but not for Rb binding. J. Virol. 67, 3142\u20133150 (1993).","journal-title":"J. Virol."},{"key":"2083_CR161","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00432-023-05511-6","volume":"150","author":"S He","year":"2024","unstructured":"He, S. et al. Human papillomavirus E7 protein induces homologous recombination defects and PARPi sensitivity. J. Cancer Res. Clin. Oncol. 150, 27 (2024).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2083_CR162","doi-asserted-by":"publisher","first-page":"19552","DOI":"10.1073\/pnas.1906102116","volume":"116","author":"J Sitz","year":"2019","unstructured":"Sitz, J. et al. Human papillomavirus E7 oncoprotein targets RNF168 to hijack the host DNA damage response. Proc. Natl. Acad. Sci. USA 116, 19552\u201319562 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2083_CR163","doi-asserted-by":"publisher","first-page":"4773","DOI":"10.1128\/MCB.21.14.4773-4784.2001","volume":"21","author":"SA Ezhevsky","year":"2001","unstructured":"Ezhevsky, S. A., Ho, A., Becker-Hapak, M., Davis, P. K. & Dowdy, S. F. Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo. Mol. Cell Biol. 21, 4773\u20134784 (2001).","journal-title":"Mol. Cell Biol."},{"key":"2083_CR164","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12929-022-00818-x","volume":"29","author":"L Zhou","year":"2022","unstructured":"Zhou, L. et al. Post-translational modifications on the retinoblastoma protein. J. Biomed. Sci. 29, 33 (2022).","journal-title":"J. Biomed. Sci."},{"key":"2083_CR165","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.molcel.2019.03.020","volume":"74","author":"BR Topacio","year":"2019","unstructured":"Topacio, B. R. et al. Cyclin D-Cdk4,6 drives cell-cycle progression via the retinoblastoma protein\u2019s C-terminal helix. Mol. Cell 74, 758\u2013770.e754 (2019).","journal-title":"Mol. Cell"},{"key":"2083_CR166","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.bbrc.2020.09.127","volume":"533","author":"L Chen","year":"2020","unstructured":"Chen, L. et al. Cyclin Y binds and activates CDK4 to promote the G1\/S phase transition in hepatocellular carcinoma cells via Rb signaling. Biochem. Biophys. Res. Commun. 533, 1162\u20131169 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2083_CR167","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6413-7","volume":"19","author":"SS Boon","year":"2019","unstructured":"Boon, S. S. et al. Human papillomavirus type 18 oncoproteins exert their oncogenicity in esophageal and tongue squamous cell carcinoma cell lines distinctly. BMC Cancer 19, 1211 (2019).","journal-title":"BMC Cancer"},{"key":"2083_CR168","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1101\/gad.9.19.2335","volume":"9","author":"S Cheng","year":"1995","unstructured":"Cheng, S., Schmidt-Grimminger, D. C., Murant, T., Broker, T. R. & Chow, L. T. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev. 9, 2335\u20132349 (1995).","journal-title":"Genes Dev."},{"key":"2083_CR169","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1101\/gad.11.16.2090","volume":"11","author":"JO Funk","year":"1997","unstructured":"Funk, J. O. et al. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev. 11, 2090\u20132100 (1997).","journal-title":"Genes Dev."},{"key":"2083_CR170","first-page":"2323","volume":"13","author":"K Zerfass-Thome","year":"1996","unstructured":"Zerfass-Thome, K. et al. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 13, 2323\u20132330 (1996).","journal-title":"Oncogene"},{"key":"2083_CR171","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10495-023-01812-w","volume":"28","author":"C Yadav","year":"2023","unstructured":"Yadav, C. et al. Overview of genetic and epigenetic regulation of human papillomavirus and apoptosis in cervical cancer. Apoptosis 28, 683\u2013701 (2023).","journal-title":"Apoptosis"},{"key":"2083_CR172","doi-asserted-by":"publisher","first-page":"8695","DOI":"10.1128\/JVI.00579-08","volume":"82","author":"ME McLaughlin-Drubin","year":"2008","unstructured":"McLaughlin-Drubin, M. E., Huh, K. W. & M\u00fcnger, K. Human papillomavirus type 16 E7 oncoprotein associates with E2F6. J. Virol. 82, 8695\u20138705 (2008).","journal-title":"J. Virol."},{"key":"2083_CR173","doi-asserted-by":"crossref","unstructured":"James, C. D. et al. Restoring the DREAM complex inhibits the proliferation of high-risk HPV positive human cells. Cancers 13, 489 (2021).","DOI":"10.3390\/cancers13030489"},{"key":"2083_CR174","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1073\/pnas.1009933108","volume":"108","author":"ME McLaughlin-Drubin","year":"2011","unstructured":"McLaughlin-Drubin, M. E., Crum, C. P. & M\u00fcnger, K. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc. Natl. Acad. Sci. USA 108, 2130\u20132135 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2083_CR175","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/1541-7786.MCR-19-1114","volume":"18","author":"X Cui","year":"2020","unstructured":"Cui, X. et al. miR-106a regulates cell proliferation and autophagy by targeting LKB1 in HPV-16-associated cervical cancer. Mol. Cancer Res. 18, 1129\u20131141 (2020).","journal-title":"Mol. Cancer Res."},{"key":"2083_CR176","doi-asserted-by":"publisher","first-page":"e1008624","DOI":"10.1371\/journal.ppat.1008624","volume":"16","author":"EL Morgan","year":"2020","unstructured":"Morgan, E. L. et al. MicroRNA-18a targeting of the STK4\/MST1 tumour suppressor is necessary for transformation in HPV positive cervical cancer. PLoS Pathog. 16, e1008624 (2020).","journal-title":"PLoS Pathog."},{"key":"2083_CR177","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41417-023-00682-3","volume":"31","author":"Q Peng","year":"2024","unstructured":"Peng, Q. et al. HPV E6\/E7: insights into their regulatory role and mechanism in signaling pathways in HPV-associated tumor. Cancer Gene Ther. 31, 9\u201317 (2024).","journal-title":"Cancer Gene Ther."},{"key":"2083_CR178","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07150-3","volume":"20","author":"JM Azevedo Martins","year":"2020","unstructured":"Azevedo Martins, J. M., Rabelo-Santos, S. H., do Amaral Westin, M. C. & Zeferino, L. C. Tumoral and stromal expression of MMP-2, MMP-9, MMP-14, TIMP-1, TIMP-2, and VEGF-A in cervical cancer patient survival: a competing risk analysis. BMC Cancer 20, 660 (2020).","journal-title":"BMC Cancer"},{"key":"2083_CR179","doi-asserted-by":"publisher","first-page":"e33585","DOI":"10.1371\/journal.pone.0033585","volume":"7","author":"LB Cardeal","year":"2012","unstructured":"Cardeal, L. B. et al. HPV16 oncoproteins induce MMPs\/RECK-TIMP-2 imbalance in primary keratinocytes: possible implications in cervical carcinogenesis. PLoS ONE 7, e33585 (2012).","journal-title":"PLoS ONE"},{"key":"2083_CR180","doi-asserted-by":"publisher","first-page":"8820","DOI":"10.1128\/JVI.02363-07","volume":"82","author":"S Yoshida","year":"2008","unstructured":"Yoshida, S., Kajitani, N., Satsuka, A., Nakamura, H. & Sakai, H. Ras modifies proliferation and invasiveness of cells expressing human papillomavirus oncoproteins. J. Virol. 82, 8820\u20138827 (2008).","journal-title":"J. Virol."},{"key":"2083_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2023.102041","volume":"82","author":"S Chakraborti","year":"2023","unstructured":"Chakraborti, S. et al. Induction of epithelial to mesenchymal transition in HPV16 E6\/E7 oncogene transfected C33A cell line. Tissue Cell 82, 102041 (2023).","journal-title":"Tissue Cell"},{"key":"2083_CR182","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3892\/ol.2011.512","volume":"3","author":"YM Cheng","year":"2012","unstructured":"Cheng, Y. M., Chou, C. Y., Hsu, Y. C., Chen, M. J. & Wing, L. Y. The role of human papillomavirus type 16 E6\/E7 oncoproteins in cervical epithelial-mesenchymal transition and carcinogenesis. Oncol. Lett. 3, 667\u2013671 (2012).","journal-title":"Oncol. Lett."},{"key":"2083_CR183","doi-asserted-by":"crossref","unstructured":"Matarrese, P., Vona, R., Ascione, B., Paggi, M. G. & Mileo, A. M. Physical interaction between HPV16E7 and the actin-binding protein gelsolin regulates epithelial-mesenchymal transition via HIPPO-YAP axis. Cancers 13, 353 (2021).","DOI":"10.3390\/cancers13020353"},{"key":"2083_CR184","doi-asserted-by":"crossref","unstructured":"Guti\u00e9rrez-Hoya, A. & Soto-Cruz, I. Role of the JAK\/STAT pathway in cervical cancer: its relationship with HPV E6\/E7 oncoproteins. Cells 9, 2297 (2020).","DOI":"10.3390\/cells9102297"},{"key":"2083_CR185","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1158\/1078-0432.CCR-17-3775","volume":"24","author":"K Srivastava","year":"2018","unstructured":"Srivastava, K. et al. \u0394Np63\u03b3\/SRC\/Slug signaling axis promotes epithelial-to-mesenchymal transition in squamous cancers. Clin. Cancer Res. 24, 3917\u20133927 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2083_CR186","doi-asserted-by":"crossref","unstructured":"Carrillo-Beltr\u00e1n, D. et al. Human papillomavirus 16 E7 promotes EGFR\/PI3K\/AKT1\/NRF2 signaling pathway contributing to PIR\/NF-\u03baB activation in oral cancer cells. Cancers 12, 1904 (2020).","DOI":"10.3390\/cancers12071904"},{"key":"2083_CR187","doi-asserted-by":"crossref","unstructured":"Carrillo, D. et al. Upregulation of PIR gene expression induced by human papillomavirus E6 and E7 in epithelial oral and cervical cells. Open Biol. 7, 170111 (2017).","DOI":"10.1098\/rsob.170111"},{"key":"2083_CR188","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/carcin\/bgad008","volume":"44","author":"J Hu","year":"2023","unstructured":"Hu, J. et al. The HPV16 E6, E7\/miR-23b-3p\/ICAT signaling axis promotes proliferation, migration, invasion and EMT of cervical cancer cells. Carcinogenesis 44, 221\u2013231 (2023).","journal-title":"Carcinogenesis"},{"key":"2083_CR189","doi-asserted-by":"crossref","unstructured":"Lo Cigno, I. et al. Human papillomavirus E7 oncoprotein subverts host innate immunity via SUV39H1-mediated epigenetic silencing of immune sensor genes. J. Virol. 94, 10\u20131128 (2020).","DOI":"10.1128\/JVI.01812-19"},{"key":"2083_CR190","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.4049\/jimmunol.178.5.3186","volume":"178","author":"UA Hasan","year":"2007","unstructured":"Hasan, U. A. et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J. Immunol. 178, 3186\u20133197 (2007).","journal-title":"J. Immunol."},{"key":"2083_CR191","doi-asserted-by":"crossref","unstructured":"Lo Cigno, I., Calati, F., Albertini, S. & Gariglio, M. Subversion of host innate immunity by human papillomavirus oncoproteins. Pathogens 9, 292 (2020).","DOI":"10.3390\/pathogens9040292"},{"key":"2083_CR192","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2022.109449","volume":"731","author":"J Ling","year":"2022","unstructured":"Ling, J. et al. Human papillomavirus 16 E6\/E7 contributes to immune escape and progression of cervical cancer by regulating miR-142-5p\/PD-L1 axis. Arch. Biochem. Biophys. 731, 109449 (2022).","journal-title":"Arch. Biochem. Biophys."},{"key":"2083_CR193","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1099\/vir.0.054486-0","volume":"94","author":"F Zhou","year":"2013","unstructured":"Zhou, F., Chen, J. & Zhao, K. N. Human papillomavirus 16-encoded E7 protein inhibits IFN-\u03b3-mediated MHC class I antigen presentation and CTL-induced lysis by blocking IRF-1 expression in mouse keratinocytes. J. Gen. Virol. 94, 2504\u20132514 (2013).","journal-title":"J. Gen. Virol."},{"key":"2083_CR194","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1038\/sj.onc.1210798","volume":"27","author":"G Bottley","year":"2008","unstructured":"Bottley, G. et al. High-risk human papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells. Oncogene 27, 1794\u20131799 (2008).","journal-title":"Oncogene"},{"key":"2083_CR195","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/23962","volume":"396","author":"T Kiyono","year":"1998","unstructured":"Kiyono, T. et al. Both Rb\/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396, 84\u201388 (1998).","journal-title":"Nature"},{"key":"2083_CR196","doi-asserted-by":"publisher","first-page":"7033","DOI":"10.1073\/pnas.1819534116","volume":"116","author":"J Hatterschide","year":"2019","unstructured":"Hatterschide, J. et al. PTPN14 degradation by high-risk human papillomavirus E7 limits keratinocyte differentiation and contributes to HPV-mediated oncogenesis. Proc. Natl. Acad. Sci. USA 116, 7033\u20137042 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2083_CR197","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.virol.2011.12.023","volume":"425","author":"ER Vandermark","year":"2012","unstructured":"Vandermark, E. R. et al. Human papillomavirus type 16 E6 and E 7 proteins alter NF-kB in cultured cervical epithelial cells and inhibition of NF-kB promotes cell growth and immortalization. Virology 425, 53\u201360 (2012).","journal-title":"Virology"},{"key":"2083_CR198","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jama.2018.10897","volume":"320","author":"SJ Curry","year":"2018","unstructured":"Curry, S. J. et al. Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. Jama 320, 674\u2013686 (2018).","journal-title":"Jama"},{"key":"2083_CR199","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1001\/jama.2023.13174","volume":"330","author":"RB Perkins","year":"2023","unstructured":"Perkins, R. B., Wentzensen, N., Guido, R. S. & Schiffman, M. Cervical cancer screening: a review. JAMA 330, 547\u2013558 (2023).","journal-title":"JAMA"},{"key":"2083_CR200","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/LGT.0000000000000529","volume":"24","author":"D Egemen","year":"2020","unstructured":"Egemen, D. et al. Risk estimates supporting the 2019 ASCCP risk-based management consensus guidelines. J. Low. Genit. Trac. Dis. 24, 132\u2013143 (2020).","journal-title":"J. Low. Genit. Trac. Dis."},{"key":"2083_CR201","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jamainternmed.2019.0306","volume":"179","author":"N Wentzensen","year":"2019","unstructured":"Wentzensen, N. et al. Clinical evaluation of human papillomavirus screening with p16\/Ki-67 dual stain triage in a large organized cervical cancer screening program. JAMA Intern. Med. 179, 881\u2013888 (2019).","journal-title":"JAMA Intern. Med."},{"key":"2083_CR202","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1158\/1078-0432.CCR-21-3710","volume":"28","author":"R van den Helder","year":"2022","unstructured":"van den Helder, R. et al. HPV and DNA methylation testing in urine for cervical intraepithelial neoplasia and cervical cancer detection. Clin. Cancer Res. 28, 2061\u20132068 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2083_CR203","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1002\/ijc.34444","volume":"152","author":"S Budhathoki","year":"2023","unstructured":"Budhathoki, S. et al. A risk prediction model for head and neck cancers incorporating lifestyle factors, HPV serology and genetic markers. Int. J. Cancer 152, 2069\u20132080 (2023).","journal-title":"Int. J. Cancer"},{"key":"2083_CR204","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1002\/ijc.32548","volume":"146","author":"J Ren","year":"2020","unstructured":"Ren, J. et al. Multiple imputation and clinico-serological models to predict human papillomavirus status in oropharyngeal carcinoma: an alternative when tissue is unavailable. Int. J. Cancer 146, 2166\u20132174 (2020).","journal-title":"Int. J. Cancer"},{"key":"2083_CR205","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/DHPS.S37273","volume":"4","author":"S Naryshkin","year":"2012","unstructured":"Naryshkin, S. & Austin, R. M. Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening. Drug Health. Patient Saf. 4, 167\u2013172 (2012).","journal-title":"Drug Health. Patient Saf."},{"key":"2083_CR206","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/LGT.0b013e3182909f86","volume":"18","author":"S Igidbashian","year":"2014","unstructured":"Igidbashian, S. et al. Tissue genotyping of 37 in situ and invasive cervical cancer with a concomitant negative HC2 HPV DNA test. J. Low. Genit. Trac. Dis. 18, 87\u201391 (2014).","journal-title":"J. Low. Genit. Trac. Dis."},{"key":"2083_CR207","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ygyno.2010.09.013","volume":"120","author":"G Coquillard","year":"2011","unstructured":"Coquillard, G., Palao, B. & Patterson, B. K. Quantification of intracellular HPV E6\/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA. Gynecol. Oncol. 120, 89\u201393 (2011).","journal-title":"Gynecol. Oncol."},{"key":"2083_CR208","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ygyno.2022.06.012","volume":"166","author":"F Sy","year":"2022","unstructured":"Sy, F. et al. Accuracy of HPV testing on self-collected and clinician-collected samples for different screening strategies in African settings: a systematic review and meta-analysis. Gynecol. Oncol. 166, 358\u2013368 (2022).","journal-title":"Gynecol. Oncol."},{"key":"2083_CR209","doi-asserted-by":"publisher","first-page":"22","DOI":"10.7326\/M19-1182","volume":"172","author":"JF Laprise","year":"2020","unstructured":"Laprise, J. F. et al. Effectiveness and cost-effectiveness of human papillomavirus vaccination through age 45 years in the United States. Ann. Intern. Med. 172, 22\u201329 (2020).","journal-title":"Ann. Intern. Med."},{"key":"2083_CR210","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1158\/1055-9965.EPI-20-0846","volume":"30","author":"JM Mix","year":"2021","unstructured":"Mix, J. M., Van Dyne, E. A., Saraiya, M., Hallowell, B. D. & Thomas, C. C. Assessing impact of HPV vaccination on cervical cancer incidence among women aged 15-29 years in the United States, 1999-2017: an ecologic study. Cancer Epidemiol. Biomark. Prev. 30, 30\u201337 (2021).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"2083_CR211","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3389\/fimmu.2020.00188","volume":"11","author":"AR Garbuglia","year":"2020","unstructured":"Garbuglia, A. R., Lapa, D., Sias, C., Capobianchi, M. R. & Del Porto, P. The use of both therapeutic and prophylactic vaccines in the therapy of papillomavirus disease. Front. Immunol. 11, 188 (2020).","journal-title":"Front. Immunol."},{"key":"2083_CR212","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ygyno.2017.04.004","volume":"146","author":"DM Harper","year":"2017","unstructured":"Harper, D. M. & DeMars, L. R. HPV vaccines\u2014a review of the first decade. Gynecol. Oncol. 146, 196\u2013204 (2017).","journal-title":"Gynecol. Oncol."},{"key":"2083_CR213","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1016\/j.scib.2023.09.020","volume":"68","author":"YM Hu","year":"2023","unstructured":"Hu, Y. M. et al. Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6\/11\/16\/18\/31\/33\/45\/52\/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial. Sci. Bull. 68, 2448\u20132455 (2023).","journal-title":"Sci. Bull."},{"key":"2083_CR214","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S1470-2045(23)00480-1","volume":"24","author":"H Sharma","year":"2023","unstructured":"Sharma, H. et al. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2\/3 trial. Lancet Oncol. 24, 1321\u20131333 (2023).","journal-title":"Lancet Oncol."},{"key":"2083_CR215","doi-asserted-by":"publisher","first-page":"10085","DOI":"10.1128\/JVI.01088-09","volume":"83","author":"C Schellenbacher","year":"2009","unstructured":"Schellenbacher, C., Roden, R. & Kirnbauer, R. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J. Virol. 83, 10085\u201310095 (2009).","journal-title":"J. Virol."},{"key":"2083_CR216","doi-asserted-by":"publisher","first-page":"805695","DOI":"10.3389\/fimmu.2021.805695","volume":"12","author":"Z Yousefi","year":"2021","unstructured":"Yousefi, Z. et al. An update on human papilloma virus vaccines: history, types, protection, and efficacy. Front. Immunol. 12, 805695 (2021).","journal-title":"Front. Immunol."},{"key":"2083_CR217","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29413","volume":"96","author":"Y Saeki","year":"2024","unstructured":"Saeki, Y. et al. Effectiveness of prophylactic HPV vaccines against cervical abnormalities and HPV infection in Japan: The J-HERS 2021 multicenter study. J. Med. Virol. 96, e29413 (2024).","journal-title":"J. Med. Virol."},{"key":"2083_CR218","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1080\/14760584.2018.1548282","volume":"17","author":"M Arbyn","year":"2018","unstructured":"Arbyn, M. & Xu, L. Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials. Expert Rev. Vaccines 17, 1085\u20131091 (2018).","journal-title":"Expert Rev. Vaccines"},{"key":"2083_CR219","doi-asserted-by":"publisher","first-page":"999","DOI":"10.2147\/IJWH.S50365","volume":"6","author":"R De Vincenzo","year":"2014","unstructured":"De Vincenzo, R., Conte, C., Ricci, C., Scambia, G. & Capelli, G. Long-term efficacy and safety of human papillomavirus vaccination. Int. J. Women\u2019s Health 6, 999\u20131010 (2014).","journal-title":"Int. J. Women\u2019s Health"},{"key":"2083_CR220","doi-asserted-by":"publisher","first-page":"e0140926","DOI":"10.1371\/journal.pone.0140926","volume":"10","author":"A Godi","year":"2015","unstructured":"Godi, A., Bissett, S. L., Miller, E. & Beddows, S. Relationship between humoral immune responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 year old girls receiving Cervarix\u00ae or Gardasil\u00ae vaccine. PLoS ONE 10, e0140926 (2015).","journal-title":"PLoS ONE"},{"key":"2083_CR221","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2329450","volume":"20","author":"C Zhao","year":"2024","unstructured":"Zhao, C. et al. Opportunities and challenges for human papillomavirus vaccination in China. Hum. Vaccin Immunother. 20, 2329450 (2024).","journal-title":"Hum. Vaccin Immunother."},{"key":"2083_CR222","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.vaccine.2022.11.044","volume":"41","author":"S Joshi","year":"2023","unstructured":"Joshi, S. et al. Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination. Vaccine 41, 236\u2013245 (2023).","journal-title":"Vaccine"},{"key":"2083_CR223","doi-asserted-by":"publisher","first-page":"101224","DOI":"10.1016\/j.mam.2023.101224","volume":"94","author":"JM Skolnik","year":"2023","unstructured":"Skolnik, J. M. & Morrow, M. P. Vaccines for HPV-associated diseases. Mol. Asp. Med. 94, 101224 (2023).","journal-title":"Mol. Asp. Med."},{"key":"2083_CR224","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1097\/IGC.0000000000001235","volume":"28","author":"P Basu","year":"2018","unstructured":"Basu, P. et al. A randomized phase 2 study of ADXS11-001 Listeria monocytogenes-Listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical cancer. Int. J. Gynecol. Cancer 28, 764\u2013772 (2018).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"2083_CR225","doi-asserted-by":"crossref","unstructured":"Ikeda, Y. et al. A placebo-controlled, double-blind randomized (Phase IIB) trial of oral administration with HPV16 E7-expressing Lactobacillus, GLBL101c, for the treatment of cervical intraepithelial neoplasia grade 2 (CIN2). Vaccines 9, 329 (2021).","DOI":"10.3390\/vaccines9040329"},{"key":"2083_CR226","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1016\/j.vaccine.2018.05.009","volume":"36","author":"A Komatsu","year":"2018","unstructured":"Komatsu, A., Igimi, S. & Kawana, K. Optimization of human papillomavirus (HPV) type 16 E7-expressing lactobacillus-based vaccine for induction of mucosal E7-specific IFN\u03b3-producing cells. Vaccine 36, 3423\u20133426 (2018).","journal-title":"Vaccine"},{"key":"2083_CR227","doi-asserted-by":"crossref","unstructured":"Kawana, K. et al. Phase I and II randomized clinical trial of an oral therapeutic vaccine targeting human papillomavirus for treatment of cervical intraepithelial neoplasia 2 and 3. JNCI Cancer Spectr. 7, pkad101 (2023).","DOI":"10.1093\/jncics\/pkad101"},{"key":"2083_CR228","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/ijc.30679","volume":"141","author":"S Khan","year":"2017","unstructured":"Khan, S. et al. Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease. Int. J. Cancer 141, 393\u2013404 (2017).","journal-title":"Int. J. Cancer"},{"key":"2083_CR229","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1158\/2326-6066.CIR-22-0174","volume":"11","author":"DR Boilesen","year":"2023","unstructured":"Boilesen, D. R. et al. Efficacy and synergy with cisplatin of an adenovirus vectored therapeutic E1E2E6E7 vaccine against HPV genome-positive C3 cancers in mice. Cancer Immunol. Res. 11, 261\u2013275 (2023).","journal-title":"Cancer Immunol. Res."},{"key":"2083_CR230","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","volume":"361","author":"GG Kenter","year":"2009","unstructured":"Kenter, G. G. et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. New Engl. J. Med. 361, 1838\u20131847 (2009).","journal-title":"New Engl. J. Med."},{"key":"2083_CR231","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","volume":"5","author":"E Massarelli","year":"2019","unstructured":"Massarelli, E. et al. Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial. JAMA Oncol. 5, 67\u201373 (2019).","journal-title":"JAMA Oncol."},{"key":"2083_CR232","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00262-016-1821-x","volume":"65","author":"HN Coleman","year":"2016","unstructured":"Coleman, H. N. et al. Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination. Cancer Immunol. Immunother. 65, 563\u2013573 (2016).","journal-title":"Cancer Immunol. Immunother."},{"key":"2083_CR233","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1016\/j.vaccine.2019.04.043","volume":"37","author":"DM Da Silva","year":"2019","unstructured":"Da Silva, D. M. et al. Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease. Vaccine 37, 2915\u20132924 (2019).","journal-title":"Vaccine"},{"key":"2083_CR234","doi-asserted-by":"publisher","first-page":"869","DOI":"10.2147\/IJN.S269986","volume":"17","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. Peptide-based nanovaccines in the treatment of cervical cancer: a review of recent advances. Int. J. Nanomed. 17, 869\u2013900 (2022).","journal-title":"Int. J. Nanomed."},{"key":"2083_CR235","doi-asserted-by":"publisher","first-page":"54399","DOI":"10.1021\/acsami.0c15522","volume":"12","author":"Q Zhang","year":"2020","unstructured":"Zhang, Q. et al. Employing ATP as a new adjuvant promotes the induction of robust antitumor cellular immunity by a PLGA nanoparticle vaccine. ACS Appl. Mater. Interfaces 12, 54399\u201354414 (2020).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2083_CR236","doi-asserted-by":"publisher","first-page":"49737","DOI":"10.1021\/acsami.1c15361","volume":"13","author":"Y Song","year":"2021","unstructured":"Song, Y. et al. Precisely shaped self-adjuvanting peptide vaccines with enhanced immune responses for HPV-associated cancer therapy. ACS Appl. Mater. Interfaces 13, 49737\u201349753 (2021).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2083_CR237","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1021\/mp700126c","volume":"5","author":"W Chen","year":"2008","unstructured":"Chen, W. & Huang, L. Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine. Mol. Pharm. 5, 464\u2013471 (2008).","journal-title":"Mol. Pharm."},{"key":"2083_CR238","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00705-013-1819-z","volume":"159","author":"A Monroy-Garc\u00eda","year":"2014","unstructured":"Monroy-Garc\u00eda, A. et al. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model. Arch. Virol. 159, 291\u2013305 (2014).","journal-title":"Arch. Virol."},{"key":"2083_CR239","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.2147\/IJN.S416706","volume":"18","author":"H Chen","year":"2023","unstructured":"Chen, H. et al. Peptide-based therapeutic HPV cancer vaccine synthesized via bacterial outer membrane vesicles. Int. J. Nanomed. 18, 4541\u20134554 (2023).","journal-title":"Int. J. Nanomed."},{"key":"2083_CR240","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.2174\/138161205774414565","volume":"11","author":"AD Santin","year":"2005","unstructured":"Santin, A. D. et al. Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. Curr. Pharm. Des. 11, 3485\u20133500 (2005).","journal-title":"Curr. Pharm. Des."},{"key":"2083_CR241","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1056\/NEJM200205303462219","volume":"346","author":"AD Santin","year":"2002","unstructured":"Santin, A. D., Bellone, S., Gokden, M., Cannon, M. J. & Parham, G. P. Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. New Engl. J. Med. 346, 1752\u20131753 (2002).","journal-title":"New Engl. J. Med."},{"key":"2083_CR242","doi-asserted-by":"publisher","first-page":"5909","DOI":"10.7314\/APJCP.2014.15.14.5909","volume":"15","author":"P Ramanathan","year":"2014","unstructured":"Ramanathan, P., Ganeshrajah, S., Raghanvan, R. K., Singh, S. S. & Thangarajan, R. Development and clinical evaluation of dendritic cell vaccines for HPV related cervical cancer-a feasibility study. Asian Pac. J. Cancer Prev. 15, 5909\u20135916 (2014).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"2083_CR243","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1128\/JVI.02343-07","volume":"82","author":"AD Santin","year":"2008","unstructured":"Santin, A. D. et al. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J. Virol. 82, 1968\u20131979 (2008).","journal-title":"J. Virol."},{"key":"2083_CR244","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccell.2022.10.016","volume":"41","author":"SM Norberg","year":"2023","unstructured":"Norberg, S. M. & Hinrichs, C. S. Engineered T cell therapy for viral and non-viral epithelial cancers. Cancer Cell 41, 58\u201369 (2023).","journal-title":"Cancer Cell"},{"key":"2083_CR245","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.4161\/21645515.2014.973317","volume":"10","author":"M Tagliamonte","year":"2014","unstructured":"Tagliamonte, M., Petrizzo, A., Tornesello, M. L., Buonaguro, F. M. & Buonaguro, L. Antigen-specific vaccines for cancer treatment. Hum. Vaccin Immunother. 10, 3332\u20133346 (2014).","journal-title":"Hum. Vaccin Immunother."},{"key":"2083_CR246","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122456","volume":"340","author":"F Rezaei","year":"2024","unstructured":"Rezaei, F. et al. Development of novel HPV therapeutic vaccine constructs based on engineered exosomes and tumor cell lysates. Life Sci. 340, 122456 (2024).","journal-title":"Life Sci."},{"key":"2083_CR247","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","volume":"386","author":"CL Trimble","year":"2015","unstructured":"Trimble, C. L. et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 386, 2078\u20132088 (2015).","journal-title":"Lancet"},{"key":"2083_CR248","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1080\/21645515.2020.1823778","volume":"17","author":"PK Bhuyan","year":"2021","unstructured":"Bhuyan, P. K. et al. Durability of response to VGX-3100 treatment of HPV16\/18 positive cervical HSIL. Hum. Vaccin Immunother. 17, 1288\u20131293 (2021).","journal-title":"Hum. Vaccin Immunother."},{"key":"2083_CR249","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/1078-0432.CCR-08-1725","volume":"15","author":"CL Trimble","year":"2009","unstructured":"Trimble, C. L. et al. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2\/3. Clin. Cancer Res. 15, 361\u2013367 (2009).","journal-title":"Clin. Cancer Res."},{"key":"2083_CR250","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1158\/1078-0432.CCR-15-0234","volume":"22","author":"YY Sun","year":"2016","unstructured":"Sun, Y. Y. et al. Local HPV recombinant vaccinia boost following priming with an HPV DNA vaccine enhances local HPV-specific CD8+ T-cell-mediated tumor control in the genital tract. Clin. Cancer Res. 22, 657\u2013669 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2083_CR251","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ijrobp.2020.02.031","volume":"107","author":"Y Hasan","year":"2020","unstructured":"Hasan, Y. et al. A phase 1 trial assessing the safety and tolerability of a therapeutic DNA vaccination against HPV16 and HPV18 E6\/E7 oncogenes after chemoradiation for cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 107, 487\u2013498 (2020).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2083_CR252","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/oncolo\/oyad085","volume":"28","author":"VK Morris","year":"2023","unstructured":"Morris, V. K. et al. Phase II trial of MEDI0457 and durvalumab for patients with recurrent\/metastatic human papillomavirus-associated cancers. Oncologist 28, 618\u2013623 (2023).","journal-title":"Oncologist"},{"key":"2083_CR253","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/S1470-2045(20)30486-1","volume":"21","author":"JW Youn","year":"2020","unstructured":"Youn, J. W. et al. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial. Lancet Oncol. 21, 1653\u20131660 (2020).","journal-title":"Lancet Oncol."},{"key":"2083_CR254","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-19-1513","volume":"26","author":"YJ Choi","year":"2020","unstructured":"Choi, Y. J. et al. A phase II, prospective, randomized, multicenter, open-label study of GX-188E, an HPV DNA vaccine, in patients with cervical intraepithelial neoplasia 3. Clin. Cancer Res. 26, 1616\u20131623 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2083_CR255","doi-asserted-by":"publisher","first-page":"e1629259","DOI":"10.1080\/2162402X.2019.1629259","volume":"8","author":"C Grunwitz","year":"2019","unstructured":"Grunwitz, C. et al. HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory. Oncoimmunology 8, e1629259 (2019).","journal-title":"Oncoimmunology"},{"key":"2083_CR256","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn3464","volume":"15","author":"J Ramos da Silva","year":"2023","unstructured":"Ramos da Silva, J. et al. Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice. Sci. Transl. Med. 15, eabn3464 (2023).","journal-title":"Sci. Transl. Med."},{"key":"2083_CR257","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29309","volume":"95","author":"S Lee","year":"2023","unstructured":"Lee, S. et al. mRNA-HPV vaccine encoding E6 and E7 improves therapeutic potential for HPV-mediated cancers via subcutaneous immunization. J. Med. Virol. 95, e29309 (2023).","journal-title":"J. Med. Virol."},{"key":"2083_CR258","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00733-8","volume":"8","author":"K Qiu","year":"2023","unstructured":"Qiu, K. et al. mRNA-LNP vaccination-based immunotherapy augments CD8(+) T cell responses against HPV-positive oropharyngeal cancer. NPJ Vaccines 8, 144 (2023).","journal-title":"NPJ Vaccines"},{"key":"2083_CR259","first-page":"1055","volume":"142","author":"KD Volesky-Avellaneda","year":"2023","unstructured":"Volesky-Avellaneda, K. D., Laurie, C., Tsyruk-Romano, O., El-Zein, M. & Franco, E. L. Human papillomavirus detectability and cervical cancer prognosis: a systematic review and meta-analysis. Obstet. Gynecol. 142, 1055\u20131067 (2023).","journal-title":"Obstet. Gynecol."},{"key":"2083_CR260","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1200\/JCO.21.01930","volume":"40","author":"J Lei","year":"2022","unstructured":"Lei, J. et al. Human papillomavirus infection determines prognosis in cervical cancer. J. Clin. Oncol. 40, 1522\u20131528 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2083_CR261","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09769-w","volume":"22","author":"J Shi","year":"2022","unstructured":"Shi, J. et al. The effect of HPV DNA and p16 status on the prognosis of patients with hypopharyngeal carcinoma: a meta-analysis. BMC Cancer 22, 658 (2022).","journal-title":"BMC Cancer"},{"key":"2083_CR262","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1002\/1878-0261.12709","volume":"14","author":"S Yang","year":"2020","unstructured":"Yang, S. et al. HPV-related methylation-based reclassification and risk stratification of cervical cancer. Mol. Oncol. 14, 2124\u20132141 (2020).","journal-title":"Mol. Oncol."},{"key":"2083_CR263","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-21-0625","volume":"27","author":"E Jeannot","year":"2021","unstructured":"Jeannot, E. et al. Circulating HPV DNA as a marker for early detection of relapse in patients with cervical cancer. Clin. Cancer Res. 27, 5869\u20135877 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2083_CR264","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1146\/annurev-pathmechdis-031521-041424","volume":"18","author":"RL Ferris","year":"2023","unstructured":"Ferris, R. L. & Westra, W. Oropharyngeal carcinoma with a special focus on HPV-related squamous cell carcinoma. Annu. Rev. Pathol. 18, 515\u2013535 (2023).","journal-title":"Annu. Rev. Pathol."},{"key":"2083_CR265","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-19-0211","volume":"25","author":"BS Chera","year":"2019","unstructured":"Chera, B. S. et al. Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer. Clin. Cancer Res. 25, 4682\u20134690 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2083_CR266","doi-asserted-by":"crossref","unstructured":"Wang, Y. et al. Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer. J. Immunother. Cancer 10, (2022).","DOI":"10.1136\/jitc-2021-003667"},{"key":"2083_CR267","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1158\/2159-8290.CD-20-1760","volume":"11","author":"AA Shamseddine","year":"2021","unstructured":"Shamseddine, A. A., Burman, B., Lee, N. Y., Zamarin, D. & Riaz, N. Tumor immunity and immunotherapy for HPV-related cancers. Cancer Discov. 11, 1896\u20131912 (2021).","journal-title":"Cancer Discov."},{"key":"2083_CR268","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1002\/ijc.32344","volume":"145","author":"Y Yang","year":"2019","unstructured":"Yang, Y. et al. REBACIN\u00ae as a noninvasive clinical intervention for high-risk human papillomavirus persistent infection. Int. J. Cancer 145, 2712\u20132719 (2019).","journal-title":"Int. J. Cancer"},{"key":"2083_CR269","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.612547","volume":"11","author":"W Chen","year":"2020","unstructured":"Chen, W. et al. Nocardia rubra cell wall skeleton up-regulates T cell subsets and inhibits PD-1\/PD-L1 pathway to promote local immune status of patients with high-risk human papillomavirus infection and cervical intraepithelial neoplasia. Front. Immunol. 11, 612547 (2020).","journal-title":"Front. Immunol."},{"key":"2083_CR270","doi-asserted-by":"crossref","unstructured":"Hamar, B. et al. Imiquimod is effective in reducing cervical intraepithelial neoplasia: a systematic review and meta-analysis. Cancers 16, 1610 (2024).","DOI":"10.3390\/cancers16081610"},{"key":"2083_CR271","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1158\/1078-0432.CCR-23-3639","volume":"30","author":"SS Sheth","year":"2024","unstructured":"Sheth, S. S. et al. Randomized phase II trial of imiquimod with or without 9-valent HPV vaccine versus observation in patients with high-grade pre-neoplastic cervical lesions (NCT02864147). Clin. Cancer Res. 30, 1768\u20131777 (2024).","journal-title":"Clin. Cancer Res."},{"key":"2083_CR272","doi-asserted-by":"publisher","first-page":"e0223288","DOI":"10.1371\/journal.pone.0223288","volume":"16","author":"L Jubair","year":"2021","unstructured":"Jubair, L., Lam, A. K., Fallaha, S. & McMillan, N. A. J. CRISPR\/Cas9-loaded stealth liposomes effectively cleared established HPV16-driven tumours in syngeneic mice. PLoS ONE 16, e0223288 (2021).","journal-title":"PLoS ONE"},{"key":"2083_CR273","doi-asserted-by":"crossref","unstructured":"Ye, J., Zheng, L., He, Y. & Qi, X. Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions. MedComm 4, e368 (2023).","DOI":"10.1002\/mco2.368"},{"key":"2083_CR274","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(00)02059-6","volume":"355","author":"J van der Zee","year":"2000","unstructured":"van der Zee, J. et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 355, 1119\u20131125 (2000).","journal-title":"Lancet"},{"key":"2083_CR275","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1158\/0008-5472.CAN-15-0816","volume":"75","author":"AL Oei","year":"2015","unstructured":"Oei, A. L. et al. Hyperthermia selectively targets human papillomavirus in cervical tumors via p53-dependent apoptosis. Cancer Res. 75, 5120\u20135129 (2015).","journal-title":"Cancer Res."},{"key":"2083_CR276","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111546","volume":"41","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. m(6)A modification confers thermal vulnerability to HPV E7 oncotranscripts via reverse regulation of its reader protein IGF2BP1 upon heat stress. Cell Rep. 41, 111546 (2022).","journal-title":"Cell Rep."},{"key":"2083_CR277","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S1473-3099(22)00435-2","volume":"22","author":"FH Zhao","year":"2022","unstructured":"Zhao, F. H. et al. Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial. Lancet Infect. Dis. 22, 1756\u20131768 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"2083_CR278","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1016\/j.vaccine.2023.04.009","volume":"41","author":"J Li","year":"2023","unstructured":"Li, J. et al. Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9-45 years: a randomized, double-blind, placebo-controlled phase 1 clinical trial. Vaccine 41, 3141\u20133149 (2023).","journal-title":"Vaccine"},{"key":"2083_CR279","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1089\/hum.2014.024","volume":"25","author":"R Rosales","year":"2014","unstructured":"Rosales, R. et al. Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine. Hum. Gene Ther. 25, 1035\u20131049 (2014).","journal-title":"Hum. Gene Ther."},{"key":"2083_CR280","first-page":"5205","volume":"9","author":"PJ Baldwin","year":"2003","unstructured":"Baldwin, P. J. et al. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin. Cancer Res. 9, 5205\u20135213 (2003).","journal-title":"Clin. Cancer Res."},{"key":"2083_CR281","doi-asserted-by":"publisher","first-page":"169.e161","DOI":"10.1016\/j.ajog.2010.09.020","volume":"204","author":"JL Brun","year":"2011","unstructured":"Brun, J. L. et al. Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am. J. Obstet. Gynecol. 204, 169.e161\u2013168 (2011).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"2083_CR282","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.112981","volume":"191","author":"E Borcoman","year":"2023","unstructured":"Borcoman, E. et al. Phase Ib\/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers. Eur. J. Cancer 191, 112981 (2023).","journal-title":"Eur. J. Cancer"},{"key":"2083_CR283","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ymthe.2020.11.002","volume":"29","author":"FL Komdeur","year":"2021","unstructured":"Komdeur, F. L. et al. First-in-human phase I clinical trial of an SFV-based RNA replicon cancer vaccine against HPV-induced cancers. Mol. Ther. 29, 611\u2013625 (2021).","journal-title":"Mol. Ther."},{"key":"2083_CR284","doi-asserted-by":"crossref","unstructured":"Pellom, S. T. et al. Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009. JCI Insight 6, (2021).","DOI":"10.1172\/jci.insight.141912"},{"key":"2083_CR285","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.732166","volume":"11","author":"H Lauterbach","year":"2021","unstructured":"Lauterbach, H. et al. Development and characterization of a novel non-lytic cancer immunotherapy using a recombinant arenavirus vector platform. Front. Oncol. 11, 732166 (2021).","journal-title":"Front. Oncol."},{"key":"2083_CR286","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1016\/S0264-410X(02)00350-X","volume":"20","author":"A de Jong","year":"2002","unstructured":"de Jong, A. et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 20, 3456\u20133464 (2002).","journal-title":"Vaccine"},{"key":"2083_CR287","doi-asserted-by":"crossref","unstructured":"Smalley Rumfield, C., Pellom, S. T., Morillon Ii, Y. M., Schlom, J. & Jochems, C. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. J. Immunother. Cancer 8, (2020).","DOI":"10.1136\/jitc-2020-000612"},{"key":"2083_CR288","first-page":"753427","volume":"2013","author":"M Karkada","year":"2013","unstructured":"Karkada, M., Quinton, T., Blackman, R. & Mansour, M. Tumor inhibition by DepoVax-based cancer vaccine is accompanied by reduced regulatory\/suppressor cell proliferation and tumor infiltration. ISRN Oncol. 2013, 753427 (2013).","journal-title":"ISRN Oncol."},{"key":"2083_CR289","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ygyno.2015.11.026","volume":"140","author":"RD Alvarez","year":"2016","unstructured":"Alvarez, R. D. et al. A pilot study of pNGVL4a-CRT\/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2\/3 (CIN2\/3). Gynecol. Oncol. 140, 245\u2013252 (2016).","journal-title":"Gynecol. Oncol."},{"key":"2083_CR290","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1158\/1078-0432.CCR-22-1987","volume":"29","author":"C Aggarwal","year":"2023","unstructured":"Aggarwal, C. et al. Safety and efficacy of MEDI0457 plus durvalumab in patients with human papillomavirus-associated recurrent\/metastatic head and neck squamous cell carcinoma. Clin. Cancer Res. 29, 560\u2013570 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2083_CR291","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6317","volume":"5","author":"TJ Kim","year":"2014","unstructured":"Kim, T. J. et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat. Commun. 5, 5317 (2014).","journal-title":"Nat. Commun."},{"key":"2083_CR292","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00262-020-02720-7","volume":"70","author":"J Chandra","year":"2021","unstructured":"Chandra, J. et al. A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC). Cancer Immunol. Immunother. 70, 743\u2013753 (2021).","journal-title":"Cancer Immunol. Immunother."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-02083-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-02083-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-02083-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T02:53:40Z","timestamp":1737687220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-02083-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":292,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2083"],"URL":"https:\/\/doi.org\/10.1038\/s41392-024-02083-w","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"24 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}